Skip to main content
MedPathMedPath Home
Clinical Trials/NL-OMON35263
NL-OMON35263
Completed
Not Applicable

*Diabetes and vascular complications: normoxia versus hypoxia* - DM-Hypoxia

niversitair Medisch Centrum Sint Radboud0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsdiabetes mellitus type 210018424

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
diabetes mellitus type 2
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
20
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
December 13, 2012
Last Updated
last year
Study Type
Observational non invasive

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • •Diagnosed with type 2 diabetes mellitus at least 2 years ago

Exclusion Criteria

  • •\- Cardiovascular disease
  • •\- Hypercholesterolemia and/or subjects on cholesterol\-lowering drugs
  • •\- Hypertension (\>160 mmHg systolic and/or \>90 mmHg diastolic pressure) and/or subjects on antihypertensive drugs
  • •\- Type I diabetes mellitus
  • •\- Older than 65 years
  • •\- Subjects with vascular complications due to type 2 diabetes mellitus (e.g. diabetic foot ulcer)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Diabetes and vascular complications: the role of endothelin and physical inactivity’
EUCTR2009-015602-18-NLActelion Pharmaceuticals
Not yet recruiting
Not Applicable
Study on complications of diabetes and risk of heart attack
CTRI/2019/01/017120Osmania Medical College
Completed
Not Applicable
Microvascular complications of diabetes mellitusmicrovascular complications in patients with diabetes type 1 and 2E14.3
DRKS00007880niversitätsklinikum Heidelberg, Klinik für Endokrinologie, Stoffwechsel und Klinische Chemie502
Active, not recruiting
Phase 4
ASCEND PLUS - a research study to test whether a treatment called oral semaglutide can protect people with type 2 diabetes from heart attacks, strokes, and other health problems
ISRCTN76193287niversity of Oxford20,000
Completed
Not Applicable
Clinical benefit for diabetic vascular complication on non-invasive measurement of advanced glycogen endproduct level in type 2 diabetes
JPRN-UMIN000024756Human Ethics Review Committee of Kumamoto University600